ACAD Stock Overview
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ACAD from our risk checks.
ACADIA Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.29 |
| 52 Week High | US$33.99 |
| 52 Week Low | US$13.73 |
| Beta | 0.57 |
| 1 Month Change | -18.57% |
| 3 Month Change | -3.84% |
| 1 Year Change | 43.06% |
| 3 Year Change | -42.11% |
| 5 Year Change | 12.03% |
| Change since IPO | 247.61% |
Recent News & Updates
Recent updates
Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price
May 22
Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah
Oct 19FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide
Sep 12Acadia: Powerful Unfolding Catalysts
Aug 03Acadia Pharma submits marketing application to FDA for trofinetide to treat Rett syndrome
Jul 18FDA AdComm Rejects Nuplazid This Time But Acadia's Race Isn't Run Yet
Jun 29Companies Like ACADIA Pharmaceuticals (NASDAQ:ACAD) Can Afford To Invest In Growth
May 07Acadia: Catalysts Stacking
Apr 28Acadia's NUPLAZID, FDA's Second Chance To Get Alzheimer's Right
Feb 22Acadia: Big News On The Near Horizon
Dec 08Acadia Pharmaceuticals: Refunding A Former Champion
Sep 29Acadia's Essential Questions Heading Into Q2 2021 Earnings
Jul 30Here's Why We Think ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation Looks Fair for the time being
Jun 16Acadia's Big Reveal
May 10Acadia maintains 2021 sales guidance as Q1 net sales rise 18%
May 05Shareholder Returns
| ACAD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.6% | -1.5% | -2.7% |
| 1Y | 43.1% | 11.8% | 16.8% |
Return vs Industry: ACAD exceeded the US Biotechs industry which returned 11.8% over the past year.
Return vs Market: ACAD exceeded the US Market which returned 16.8% over the past year.
Price Volatility
| ACAD volatility | |
|---|---|
| ACAD Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in US Market | 14.2% |
| 10% least volatile stocks in US Market | 2.5% |
Stable Share Price: ACAD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: ACAD's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 540 | Steve Davis | https://acadia.com |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer’s disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms.
ACADIA Pharmaceuticals Inc. Fundamentals Summary
| ACAD fundamental statistics | |
|---|---|
| Market Cap | US$3.81b |
| Earnings (TTM) | -US$110.81m |
| Revenue (TTM) | US$550.90m |
6.9x
P/S Ratio-34.4x
P/E RatioIs ACAD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACAD income statement (TTM) | |
|---|---|
| Revenue | US$550.90m |
| Cost of Revenue | US$298.66m |
| Gross Profit | US$252.24m |
| Other Expenses | US$363.05m |
| Earnings | -US$110.81m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.68 |
| Gross Margin | 45.79% |
| Net Profit Margin | -20.12% |
| Debt/Equity Ratio | 0% |
How did ACAD perform over the long term?
See historical performance and comparison